Scientific Program

Day 1: December 17 (Friday) 2021
Room 1

7:50-8:00 Opening Ceremony
Dr. Mitsuhiko Moriyama (President of APASL Oncology 2021)

8:00-9:00 Morning Seminar (1) (Sponsored by Chugai Pharmaceutical Co., Ltd.)
Chair: Dr. Masao Omata (Japan)
Toward Further Advancement of Molecular Targeted Therapy Using Liquid Biopsy in HCC
Dr. Sadakatsu Ikeda (Japan)

9:10-10:40 Session 1: Molecular Mechanism of HCC (1)
Chairs: Dr. Ranjit Ray (USA)/Dr. Naoshi Nishida (Japan)
9:10-9:25 1-1 Risk Assessment of Hepatocellular Carcinoma Development-clinical and Molecular Perspective
Dr. Ryota Masuzaki (Japan)
9:25-9:40 1-2 Role of FGF19/FGFR4 Signaling and Potential of Serum FGF19 as a Biomarker in Hepatocellular Carcinoma.
Dr. Tetsuhiro Chiba (Japan)
9:40-9:55 1-3 Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression
Dr. Yutaka Midorikawa (Japan)
9:55-10:10 1-4 Linking IncRNA Linc-Pint with Liver Disease
Dr. Ratna B. Ray (USA)
10:10-10:25 1-5 Genetic and Epigenetic Basis of Pediatric Liver Tumors
Dr. Hiroyuki Aburatani (Japan)
10:25-10:40 Discussion Time

10:50-12:20 Session 2: Intermediate-stage HCC (TKI, Lenvatinib) (1)
Chairs: Dr. Masafumi Ikeda (Japan)/Dr. Tawesak Tawandee (Thailand)
10:50-11:05 2-1 Analysis for Transition of Molecular Target Agent Therapy and Prognosis in Advanced Hepatocellular Carcinoma
Dr. Kazufumi Kobayashi (Japan)
11:05-11:20 2-2 HCC Following Hepatitis C Virus Eradication
Dr. Massimo Colombo (Italy)
11:20-11:35 2-3 Integrating Systemic Therapy into Multidisciplinary Treatment of HCC
Dr. Ann-Lii Cheng (Taiwan)
2-4 Systemic Treatment Including Lenvatinib in Patients with BCLC-B Stage Hepatocellular Carcinoma  
Dr. Atsushi Hiraoka (Japan)

2-5 Identification of Tumor Factors of Hepatocellular Carcinoma that Decrease the Efficacy of Immune Checkpoint Inhibitors  
Dr. Masao Honda (Japan)

12:05-12:20 Discussion Time

12:30-13:30 Luncheon Seminar (1) (Sponsored by Chugai Pharmaceutical Co., Ltd.)  
Chair: Dr. Masatoshi Kudo (Japan)
Novel Cancer Immunotherapy for Hepatocellular Carcinoma: Evidence and Management  
Dr. Masafumi Ikeda (Japan)
Exploring Next-Gen Systemic Therapy for HCC: What Have We Learned?  
Dr. Ann-Lii Cheng (Taiwan)

13:40-14:20 President Lecture (Sponsored by Towa Pharmaceutical Co., Ltd.)  
Chair: Dr. Masao Omata (Japan)
Considering the Occurrence of Liver Cancer from Chronic Hepatitis C / Cirrhosis in Japan  
Dr. Mitsuhiko Moriyama (President of APASL Oncology 2021)

14:30-16:00 Session 3: Intermediate-stage HCC (2)  
Chairs: Dr. George Lau (China)/Dr. Atsumasa Komori (Japan)/Dr. Tsutomu Masaki (Japan)
14:30-14:45 3-1 Treatment Strategy for Intermediate Stage HCC  
Dr. Masafumi Ikeda (Japan)
14:45-15:00 3-2 Paradigm Shift with Drug Therapy in the Treatment of Intermediate-Stage Hepatocellular Carcinoma  
Dr. Tatsuya Yamashita (Japan)
15:00-15:15 3-3 Treatment Strategy for Intermediate Stage HCC with Consideration of Maintaining Liver Function  
Dr. Naoya Kato (Japan)
15:15-15:30 3-4 Systemic Therapy in the Intermediate Stage HCC: Current Evidence and Future Perspective  
Dr. Changhoon Yoo (Korea)
15:30-15:45 3-5 Treatment Strategy of Intermediate-stage HCC: ABC Conversion Therapy  
Dr. Masatoshi Kudo (Japan)
15:45-16:00 Discussion Time

16:10-17:40 Session 4: Pathology of HCC  
Chairs: Dr. Shinichi Aishima (Japan)/Dr. Kenichi Harada (Japan)/Dr. Michiie Sakamoto (Japan)
16:10-16:25 4-1 Tumour Heterogeneity of HCC and Its Clinical Relevance  
Dr. Mina Komuta (Japan)
16:25-16:40  4-2 Pathological Features of Tumor Microenvironment of HCC
             Dr. Michiie Sakamoto (Japan)
16:40-16:55  4-3 Genomic Structures and Carcinogenesis of HBV Integrations in Liver Cancer
             Dr. Hidewaki Nakagawa (Japan)
16:55-17:10  4-4 Update in HCC Pathology
             Dr. Young Nyun Park (Korea)
17:10-17:25  4-5 Morphological Subtypes of Hepatocellular Carcinoma
             Dr. Shinichi Aishima (Japan)
17:25-17:40  Discussion Time

17:50-19:20 Session 5: Oncoimmunotherapy for HCC
Chairs: Dr. Shiv K. Sarin (India)/Dr. Masao Omata (Japan)
17:50-18:05  5-1 Mechanism of Resistance to Immunotherapy for Hepatocellular Carcinoma
             Dr. Kazuomi Ueshima (Japan)
18:05-18:20  5-2 Dramatic Transformation of Treatments in Patients with Advanced Hepatocellular
             Carcinoma
             Dr. Sadahisa Ogasawara (Japan)
18:20-18:35  5-3 Oncoimmunotherapy for HCC (Tentative)
             Dr. Thomas Yau (China)
18:35-18:50  5-4 Leukotrienes Derived from Tumor-Infiltrating M2 Macrophages Promote the
             Progression of Hepatocellular Carcinoma
             Dr. Takuto Nosaka (Japan)
18:50-19:05  5-5 Multiomics Profiling Identifies the Link between Intra-tumor Steatosis and Immune-
             exhaustion in Non-viral HCC
             Dr. Takahiro Kodama (Japan)
19:05-19:20  Discussion Time

19:30-20:30 Evening Seminar (Sponsored by Incyte Biosciences Japan GK)
Chair: Dr. Yukiyasu Okamura (Japan)
New Personalized Approach for Intrahepatic Cholangiocarcinoma Based on Cancer Genomic Diagnosis in
Japan
             Dr. Naoya Kato (Japan)
Pemigatinib in Cholangiocarcinoma: Targeting FGFR2 Fusions
             Dr. Arndt Vogel (Germany)
Day 1: December 17 (Friday) 2021
Room 2

8:00-9:00 Morning Seminar (2) (Sponsored by Otsuka Pharmaceutical Co., Ltd.)
Chair: Dr. Naoya Kato (Japan)
The Usefulness of Tolvaptan as a Treatment of Hepatic Edema among Advanced HCC Patients
Dr. Takamasa Ohki (Japan)
Clinical Symptoms of Liver Diseases: Pathogenesis and Treatment
Dr. Tatsuo Kanda (Japan)

9:05-10:50 Session 6: Surgery and Transplantation
Chairs: Dr. Seth J. Karp (USA)/Dr. Tadatoshi Takayama (Japan)
9:05-9:20 6-1 Placental Stem Cell Transplantation Prevented Disease Development in Ornithine Transcarbamylase Deficiency Model Mice
Dr. Toshio Miki (Japan)
9:20-9:35 6-2 Minimal Invasive Hepatectomy in the Post-SVR Era
Dr. Yuji Iimuro (Japan)
9:35-9:50 6-3 Surgery for Perihilar Cholangiocarcinoma: Resection and Transplantation
Dr. Masayuki Ohtsuka (Japan)
9:50-10:05 6-4 Management of Hepatocellular Carcinoma “Current Therapeutic Options”
Dr. Washim Jafri (Pakistan)
10:05-10:20 6-5 Proposal of Resectability for Hepatocellular Carcinoma for Future Clinical Trial
Dr. Etsuro Hatano (Japan)
10:20-10:35 6-6 Hepatoblastoma Management: From Resection To Transplantation
Dr. Mureo Kasahara (Japan)
10:35-10:50 Discussion Time

11:00-12:30 Session 7: HCC in Asia, Epidemiology (1)
Chairs: Dr. Wan Long Chuang (Taiwan)/ Dr. Necati Örmeci (Turkey)/ Dr. Fumio Imazeki (Japan)
11:00-11:15 7-1 HCC in China, Epidemiology (Tentative)
Dr. Lai Wei (China)
11:15-11:30 7-2 Epidemiological Aspects of HCC Prevention in Asia-Pacific
Dr. Manoj K Sharma (India)
11:30-11:45 7-3 Changing Epidemiology of Hepatocellular Carcinoma in Taiwan
Dr. Wan Long Chuang (Taiwan)
11:45-12:00 7-4 The magnified challenge of HCC in Bangladesh in the context of COVID-19 Pandemic
Dr. Mamun-Al Mahtab (Bangladesh)
12:00-12:15 7-5 HCC Caused by Hepatitis Delta Virus infection in Asia-Pacific
Dr. Saeed Hamid (Pakistan)
12:15-12:30 Discussion Time
### Luncheon Seminar (2) (Sponsored by Sysmex Co., Ltd.)

**Chair:** Dr. Jia-Horng Kao (Taiwan)

**M2BPGi for Liver Fibrosis and Outcome Prediction**

Dr. Tung-Hung Su (Taiwan)

### 14:30-16:00 Session 8: HCC in Asia, Epidemiology (2)

**Chairs:** Dr. Hasmik Ghazinyan (Armenia) / Dr. Tatsuya Kanto (Japan)/ Dr. Osamu Yokosuka (Japan)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td><strong>Epidemiology Hepatocellular Carcinoma (HCC) in Thailand</strong></td>
<td>Dr. Teerha Piratvisuth (Thailand)</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>Hepatocellular Carcinoma in Indonesia: Immunology View</strong></td>
<td>Dr. Rino Gani (Indonesia)</td>
</tr>
<tr>
<td>15:00</td>
<td><strong>Global Epidemiology &amp; Risk Factors of Hepatocellular Carcinoma</strong></td>
<td>Dr. Man-Fung Yuen (China)</td>
</tr>
<tr>
<td>15:15</td>
<td><strong>Epidemiology of HCC in Mongolia</strong></td>
<td>Dr. Oidov Baatarkhuu (Mongolia)</td>
</tr>
<tr>
<td>15:30</td>
<td><strong>Epidemiology of Viral Hepatitis and HCC in Japan</strong></td>
<td>Dr. Junko Tanaka (Japan)</td>
</tr>
<tr>
<td>15:45</td>
<td><strong>Discussion Time</strong></td>
<td></td>
</tr>
</tbody>
</table>

### 16:10-17:40 Session 9: Management of HCC and Complications during TKI Treatment

**Chairs:** Dr. A. Kadir Dokmeci (Turkey)/Dr. Diana A. Payawal (Philippines)/ Dr. Tetsuo Takehara (Japan)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:10</td>
<td><strong>HCC Treatment in JRCMC (Japanese Red Cross Medical Center)</strong></td>
<td>Dr. Hideo Yoshida (Japan)</td>
</tr>
<tr>
<td>16:25</td>
<td><strong>Management of Adverse Event from the Pharmacological Perspective in Patients with Hepatocellular Carcinoma Using Tyrosine Kinase Inhibitor</strong></td>
<td>Dr. Hironao Okubo (Japan)</td>
</tr>
<tr>
<td>16:40</td>
<td><strong>Management of HCC Patient with Portal Vein Thrombosis</strong></td>
<td>Dr. Shiv Kumar Sarin (India)</td>
</tr>
<tr>
<td>16:55</td>
<td><strong>Contrast-enhanced US-based Assessment of HCC Hemodynamics Related to Systemic Treatment</strong></td>
<td>Dr. Hitoshi Maruyama (Japan)</td>
</tr>
<tr>
<td>17:10</td>
<td><strong>Effective Prevention of TKI-related Vascular Damage induced Adverse Events and Maintenance of Hepatic Function by Dried Bonito Broth and Histidine</strong></td>
<td>Dr. Kenya Kamimura (Japan)</td>
</tr>
<tr>
<td>17:25</td>
<td><strong>Discussion Time</strong></td>
<td></td>
</tr>
</tbody>
</table>

### 17:50-19:20 Session 10: HCC after SVR

**Chairs:** Dr. Shuhei Nishiguchi (Japan) / Dr. Yasuhide Tanaka (Japan)/ Dr. Hiroshi Yatsuhashi (Japan)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:50</td>
<td><strong>Rapid Hepatitis C Virus Clearance by Antivirals Correlates with Immune Status of Infected Patients and Decreased Immune Related Cytokines and Chemokines</strong></td>
<td>Dr. Reina Sasaki (Japan)</td>
</tr>
</tbody>
</table>
18:05-18:20  10-2 The Clinical and Pathogenic Significance of HCC after Viral Eradication
             Dr. Min-Lung Yu (Taiwan)
18:20-18:35  10-3 Risk of Hepatocellular Carcinoma After Sustained Virological Response in Hepatitis C Virus Infection
             Dr. Yoichi Hiasa (Japan)
18:35-18:50  10-4 Development of HCC in Treated HBV Patients
             Dr. Jia-Horng Kao (Taiwan)
18:50-19:05  10-5 Gene Expression Signature Associated with HCC Development after HCV Eradication
             Dr. Yasuhito Tanaka (Japan)
19:05-19:20  Discussion Time

20:00-22:30 APASL Hepatology Webinar “Editor’s Choice” Collaborated with AASLD
**Day 1: December 17 (Friday) 2021**

**Room 3**

**9:10-10:06  Oral Free Papers (1)**

*Chairs: Dr. Jun Arai (Japan)/Dr. Takumi Kawaguchi (Japan)/Dr. Naoya Sakamoto (Japan)*

9:10-9:17  **#10046 Surgical Treatment for Multinodular HCC with Right Hepatic Vein Tumor Thrombosis: A Case Report**  
Dr. Giang Nguyen (Viet Nam)

9:17-9:24  **#10006 A Case with HCC Successfully Treated with Prednisone for Atezolizumab-Associated Grade 3 Colitis**  
Dr. Takahiro Fuji (Japan)

9:24-9:31  **#10045 New Research Trends in Onco-carcinogenesis and Nutritional Background Linked with Chronic Inflammation, Iron (Fe) Deposition, and Metabolic Changes**  
Dr. Kenichi Furuya (Japan)

9:31-9:38  **#10061 Case reports of HCC with IVC and Rt. Atrium Tumor Thrombus and Extension into Left Renal Vein**  
Dr. Parimita Barua (India)

9:38-9:45  **#10005 Novel Immuno-Oncotherapy against HCC by Targeting MICA**  
Dr. Yumi Otoyama (Japan)

9:45-9:52  **#10066 Synergistic Nanoassemblies with Enhanced Cancer Chemo-Immunotherapy**  
Dr. Xiaowei Shi (China)

9:52-9:59  **#10012 Various Uses of Ramucirumab in Real World Practice for Patients with Hepatocellular Carcinoma**  
Dr. Naoya Kanogawa (Japan)

9:59-10:06  **#10049 Regorafenib and its metabolites could induce NK cell-mediated cytotoxicity in HCC by targeting ADAM9**  
Dr. Jun Arai (Japan)

**12:30-13:30  Luncheon Seminar (3) (Sponsored by Eisai Co., Ltd./MSD K.K.)**  

*Chair: Dr. Shuntaro Obi (Japan)*

LEN-TACE Sequential Therapy as a Therapeutic Strategy for Intermediate-stage Hepatocellular Carcinoma  
Dr. Yoshiyuki Wada (Japan)

Positioning of Hepatic Arterial Infusion Chemotherapy and Lenvatinib for Advanced Hepatocellular Carcinoma  
Dr. Tatsuya Yamashita (Japan)

**14:30-15:30  Educational Seminar (1) (Sponsored by Miyarisan Pharmaceutical Co., Ltd.)**  

*Chair: Dr. Tadatoshi Takayama (Japan)*

Role of Gut Microbiota in Liver Disease and Carcinogenesis  
Dr. Nobuhiro Nakamoto (Japan)
15:40-16:50  Oral Free Papers (2)

Chairs: Dr. Yuko Nagaoki (Japan)/Dr. Hidenari Nagai (Japan)

15:40-15:47  #10004  Particle Radiotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
               Dr. Yoshiro Matsuo (Japan)

15:47-15:54  #10024  Efficacy and Safety of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma in Japan
               Dr. Tadashi Namisaki (Japan)

15:54-16:01  #10020  HCC Surveillance Remains Cost-effective Long after Hepatitis B Surface Antigen Loss: A 12-year Study
               Dr. Terry Cheuk-Fung Yip (Japan)

16:01-16:08  #10064  Hepatocellular Carcinoma Emergence in Armenia: Outcome of Multiple Risk Factors, 2019-2020
               Dr. Hasnik Levon Ghazinyan (Armenia)

16:08-16:15  #10058  Nucleic acid Analog Therapy and Liver Carcinogenesis in Patients with Chronic Hepatitis B
               Dr. Makoto Moriyama (Japan)

16:15-16:22  #10029  Impact of Viral Eradication by DAA on Clinical Outcome after Treatment for HCV Associated HCC
               Dr. Yuko Nagaoki (Japan)

16:22-16:29  #10047  The Comprehensive Prognosis of Chronic Hepatitis C after DAA Therapy for Chronic Hepatitis C
               Dr. Yuki Kanayama (Japan)

16:29-16:36  #10023  Comparison of HBV Reactivation in HCC Patients Who Received TKI and TKI with PD-1 Inhibitor
               Dr. Jin Lei (China)

16:36-16:43  #10067  Occult Hepatitis B Virus Infection in Patients with HCV-Related Hepatocellular Carcinoma
               Dr. Muhammad Abdel-Gawad (Egypt)

16:43-16:50  #10069  Bone Mineral Density in Patients with Non-Alcoholic Fatty Liver Disease
               Dr. Muhammad Abdel-Gawad (Egypt)
Day 2: December 18 (Saturday) 2021
Room 1

8:00-9:00  **Morning Seminar (3)** (Sponsored by Mitsubishi Tanabe Pharma Corporation)
Chair: Dr. Katsutoshi Tokushige (Japan)
New Findings and Future Prospects, Based on Japanese Patients of Histological Proven NAFLD in Toranomon Hospital  Dr. Norio Akuta (Japan)

9:10-10:40 Session 11: Molecular Mechanism of HCC (2)
Chairs: Dr. Shuichi Kaneko (Japan)/Dr. Shinji Tanaka (Japan)/Dr. Lai Wei (China)

9:10-9:25  11-1 The Interaction of Hepatoma Cells and Stromal Cells Via IL-6 Family Cytokines
Dr. Hayato Hikita (Japan)

9:25-9:40  11-2 Impairment of Homologous Recombination by HBx as the Mechanism for HBV-Related Hepatocarcinogenesis
Dr. Motoyuki Otsuka (Japan)

9:40-9:55  11-3 Recent Progress in Basic and Clinical Research of Liver Cancer Stem Cells
Dr. Taro Yamashita (Japan)

9:55-10:10 11-4 Genetic Alterations during Multistep Hepatocarcinogenesis Revealed by Whole Genome Sequencing
Dr. Haruhiko Takeda (Japan)

10:10-10:25 11-5 Predictive Scores for Hepatocellular Carcinoma Risk Stratification after Achieving SVR Following DAAS
Dr. Gamal Shiha (Egypt)

10:25-10:40 Discussion Time

10:50-12:20 Session 12: HAIC, TACE, RFA, Radiation
Chairs: Dr. Ji Dong-Jia (China)/Dr. Satoshi Mochida (Japan)/Dr. Hitoshi Yoshiji (Japan)

10:50-11:05 12-1 Radiofrequency Ablation for Hepatocellular Carcinoma
Dr. Ryosuke Tateishi (Japan)

11:05-11:20 12-2 Hepatic Arterial Infusion Chemotherapy (HAIC) in 2021
Dr. Shuntaro Obi (Japan)

11:20-11:35 12-3 Effective Use of Local Ablation Therapy for the Treatment of Early to Intermediate HCC
Dr. Kazuhiro Nouso (Japan)

11:35-11:50 12-4 The Key Recommendations by APASL PBC Guidance 2021
Dr. Ji Dong Jia (China)

11:50-12:05 12-5 Laparoscopic Radiofrequency Ablation in the Era of Non-viral Hepatitis
Dr. Naoki Morimoto (Japan)

12:05-12:20 Discussion Time
12:30-13:30 Luncheon Seminar (4) (Sponsored by AbbVie GK)
Chair: Dr. Masayuki Kurosaki (Japan)

Ultra-FP Treatment could be Affordable Treatment Option for Advanced Stage of HCC
Dr. Yasuteru Kondo (Japan)

Radiofrequency Ablation for Hepatocellular Carcinoma
Dr. Ryosuke Tateishi (Japan)

14:30-16:00 Session 13: Intermediate-stage HCC (TKI, Sorafenib, Regorafenib) (3)
Chairs: Dr. Manoj K Sharma (India)/Dr. Norifumi Kawada (Japan)

14:30-14:45 13-1 Exploring Tumor Microenvironment in Patients with Advanced Hepatocellular Carcinoma
Dr. Hiroaki Kanzaki (Japan)

14:45-15:00 13-2 Management Challenges for Intermediate Stage Hepatocellular Carcinoma (HCC) in the era of Systemic Therapy
Dr. Cosmas Rinaldi A. Lesmana (Indonesia)

15:00-15:15 13-3 Impact of Skeletal Muscle Volume in Patients with Intermediate-stage hepatocellular carcinoma (HCC) receiving sorafenib: A comparison with advanced HCC patients
Dr. Issei Saeki (Japan)

15:15-15:30 13-4 Mechanisms and Management of Sorafenib Resistance in Hepatocellular Carcinoma
Dr. Rakhi Maiwall (India)

15:30-15:45 13-5 Optimal Sequencing of TKI after Atezolizumab and Bevacizumab in HCC
Dr. Wei-Peng Yong (Singapore)

15:45-16:00 Discussion Time

16:10-17:40 Session 14: Intermediate-stage HCC (5) (Ramucirumab, etc.)
Chairs: Dr. Namiki Izumi (Japan)/Dr. Pei Jer Chen (Taiwan)

16:10-16:25 14-1 Systemic Therapy for Intermediate-stage Hepatocellular Carcinoma Including Real-world Data of Ramucirumab Treatment as Second or Later Line
Dr. Yutaka Yasui (Japan)

16:25-16:40 14-2 Analyses of Intermediate-stage Hepatocellular Carcinoma Patients Receiving TACE Prior to Designing Clinical Trials
Dr. Keisuke Koroki (Japan)

16:40-16:55 14-3 Hepatocellular Carcinoma Emergence in Armenia: Outcome of Multiple Risk Factors, January 2019 to March 2020 Nork Clinical Hospital of Infectious Diseases
Dr. Hasmik Ghazinyan (Armenia)

16:55-17:10 14-4 Management of Intermediate Hepatocellular Carcinoma - Past, Present and Future
Dr. George Lau (China)

17:10-17:25 14-5 Treatment Strategy of Intermediate-stage HCC: LEN-TACE Sequential Therapy
Dr. Masatoshi Kudo (Japan)
17:25-17:40 Discussion Time

17:40-17:50 Awarding Ceremony

17:50-18:00 Closing Ceremony

Dr. Mitsuhiko Moriyama (President of APASL Oncology 2021)
Day 2: December 18 (Saturday) 2021
Room 2

8:00-9:00 Morning Seminar (4) (Sponsored by Takeda Pharmaceutical Co., Ltd.)

Chair: Dr. Shinichi Takahashi (Japan)

Gastric Cancer Risk with H. Pylori Infection and Gastric Cancer Management in Japan

Dr. Kazunari Murakami (Japan)

9:10-10:40 Session 15: COVID-19 in Japan

Chairs: Dr. Masashi Mizokami (Japan)/Dr. Mitsuhiko Moriyama (Japan)

9:10-9:25 15-1 Diagnosis, Genome Surveillance and Immune Response of COVID-19

Dr. Yosuke Hirotsu (Japan)


Dr. Masaya Sugiyama (Japan)


Dr. Shuichiro Shiina (Japan)

9:55-10:10 15-4 Responses to COVID-19 Outbreaks in Healthcare Setting in Japan, January 2020 - September 2021

Dr. Takuya Yamaghishi (Japan)

10:10-10:25 15-5 COVID-19 in Japan

Dr. Hiroshi Yotsuyanagi (Japan)

10:25-10:40 Discussion Time

10:50-12:20 Session 16: Diagnosis of HCC

Chairs: Dr. Jee-Fu Huang (Taiwan)/Dr. Kiyoshi Hasegawa (Japan)/Dr. Masahiro Ogawa (Japan)

10:50-11:05 16-1 Imaging Evaluation of HCC in the Systemic Treatment Era

Dr. Takamichi Murakami (Japan)

11:05-11:20 16-2 Tumor Marker Profiles in Patients with Viral and Non-viral Hepatocellular Carcinoma

Dr. Hidenori Toyoda (Japan)

11:20-11:35 16-3 Diagnosis of HCC (Tentative)

Dr. Jin Mo Yang (Korea)

11:35-11:50 16-4 Diagnosis of Hepatocellular Carcinoma by Contrast-enhanced Ultrasound – Focusing on Early Hepatocellular Carcinoma

Dr. Hiroko Iijima (Japan)

11:50-12:05 16-5 aMAP Score Prediction of Hepatocellular Carcinoma Development in Patients with Chronic Liver Disease

Dr. Takeji Umemura (Japan)

12:05-12:20 Discussion Time
12:30-13:30 Luncheon Seminar (5) (Sponsored by Gilead Sciences K.K.)
Chair: Dr. Yoshiyuki Ueno (Japan)

Current Status of HBV Prevalence and Efforts for Eradicating Hepatic Failure by HBV Reactivation in Patients with Cancer
Dr. Sachiyo Yoshio (Japan)

Recent Advances in Systemic Therapy for Hepatocellular Carcinoma and Management of Hepatitis B Infection
Dr. Kaoru Tsuchiya (Japan)

14:30-16:00 Session 17: Intermediate-stage HCC (TKI, Lenvatinib) (4)
Chairs: Dr. Jin Mo Yang (Korea)/Dr. Kazuaki Chayama (Japan)/Dr. Takaji Torimura (Japan)

14:30-14:45 17-1 Treatment Strategy of Intermediate Stage HCC using Lenvatinib “Lenvatinib TACE Sequential Therapy”
Dr. Yusuke Kawamura (Japan)

14:45-15:00 17-2 Lenvatinib for Intermediate Stage HCC
Dr. Yoshinari Asaoka (Japan)

15:00-15:15 17-3 The Dawn of a New Era in Hepatocellular Carcinoma Treatment with Molecular Targeted Therapy and Local Therapy
Dr. Eishiro Mizukoshi (Japan)

15:15-15:30 17-4 Adjuvant Systemic Therapies in Intermediate HCC
Dr. Levent Doğanay (Turkey)

15:30-15:45 17-5 Value of Lenvatinib in the Treatment of Intermediate Stage HCC
Dr. Chun-Jen Liu (Taiwan)

15:45-16:00 Discussion Time

16:10-17:40 Session 18: Intermediate-stage HCC (6) (TKI, Lenvatinib)
Chairs: Dr. Sumiko Nagoshi (Japan)/Dr. Yoshiyuki Ueno (Japan)

16:10-16:25 18-1 Contrast-enhanced Ultrasonography for Blood Flow Detection in Hepatocellular Carcinoma During Lenvatinib Therapy
Dr. Naoki Matsumoto (Japan)

16:25-16:40 18-2 Guidelines in Evolution: Systemic Therapy for Intermediate-stage HCC
Dr. Chiun Hsu (Taiwan)

16:40-16:55 18-3 Importance of Keeping Balance Between Therapeutic Effects and Adverse Events in Lenvatinib for Hepatocellular Carcinoma—Refinement of Administration Schedule and Combination with Transarterial Therapy—
Dr. Hideki Iwamoto (Japan)

16:55-17:10 18-4 Role of tumor immunogenicity and tumor-associated macrophages in multi-kinase inhibitor responses for hepatocellular carcinoma
Dr. Pil Soo Sung (Korea)

17:10-17:25 18-5 The Prediction Model of HBV-HCC During Anti-viral Therapy
Dr. Hong You (China)

17:25-17:40 Discussion Time
Day 2: December 18 (Saturday) 2021
Room 3

8:00-9:00 Morning Seminar (5) (Sponsored by AstraZeneca)
Chair: Dr. Hiroo Imazu (Japan)

Treatment Strategies for Acid Related Disease in Primary Care-Based on Clinical Practice Guidelines for GERD 2021
Dr. Akihito Nagahara (Japan)

9:00-10:34 Oral Free Papers (3)

9:10-9:17 #10008 Contribution of dMMR to Accumulation of Somatic Mutations at Different Stages of HCC Development
Dr. Masayuki Ueno (Japan)

9:17-9:24 #10033 Genetic Discrimination between Multicentric Occurrence and Intrahepatic Metastasis in Multifocal HCC
Dr. Yuji Iimuro (Japan)

9:24-9:31 #10015 An Assistive Computational Tool for Defining the Segmental Anatomy of the Liver
Dr. Harvey Ho (New Zealand)

9:31-9:38 #10035 The Protective Role of DNA Methyltransferase 3B Against Inflammatory Hepatocarcinogenesis
Dr. Eriko Iguchi (Japan)

9:38-9:45 #10060 Utility of AFP, AFP-L3, and PIVKA-II for Hepatocellular Carcinoma Surveillance
Dr. Supot Nimanong (Thailand)

9:45-9:52 #10062 Natural Killer Cells Putative Role in Patients with HCV-Related Hepatocellular Carcinoma
Dr. Mohamed Abdel-Samiee (Egypt)

9:52-9:59 #10076 Let-7a and Let-7i as Biomarkers for CHC Patients with HCC Risk after Anti-viral Treatment
Dr. Ming-Lung Yu (Taiwan)

9:59-10:06 #10009 Post-treatment Cell-free DNA as a Predictive Biomarker in Systemic Therapy for HCC
Dr. Takuma Nakatsuka (Japan)

10:06-10:13 #10026 The Combination of ALBI and PT Predict Liver Dysfunction after TACE for HCC within Up-to-7 Criteria
Dr. Hiroaki Takaya (Japan)

10:13-10:20 #10063 MicroRNA Gene Polymorphisms and Development of Hepatocellular Carcinoma in Egyptian Patients
Dr. Mohamed Abdel-Samiee (Egypt)

10:20-10:27 #10079 Analysis of Sarcopenia in Patients with BCLC Stage B HCC who Received Atezolizumab Plus Bevacizumab
Dr. Hiroaki Matsumoto (Japan)
The Simple Product of Albumin and Platelets Indicates the Stage of Liver Fibrosis and Prognosis
Dr. Koji Fujita (Japan)

11:00-12:00 Educational Seminar (2) (Sponsored by AbbVie GK)
Chair: Dr. Junko Tanaka (Japan)
SVR & HCV-related HCC
Dr. Yoshinari Asaoka (Japan)
HCV Eradication in the SDGs Era
Dr. Hironao Okubo (Japan)